Therapeutic Research

Abstract

Twenty patients with hyperuricemia were administered febuxostat to prevent renal function decline by lowering uric acid. Patients consisted of 17 males and 3 females having age of 72±9 y（mean±SD）. Patients had hyperuricemia with chronic kidney disease （CKD）of various causes. After receiving febuxostat 20 mg daily, their serum uric acid decreased from 8.0±2.5 to 5.9±1.0 mg/dL, serum creatinine from 1.34±0.29 to 1.18±0.24 mg/dL, and estimated glomerular filtration rate（eGFR） recovered from 41.2±9.9 to 46.9±11.7 mL/min. Observed values were statistically significant（Student paired t‒test, p＜0.01）. No new gout attacks were observed under febuxostat stepwise loading. In conclusion, febuxostat is a safe and effective agent to decrease serum uric acid levels under 6.0 mg/dL. Furthermore, after receiving febuxostat, improved renal function was exhibited by all twenty CKD patients with hyperuricemia.